We are proud to announce that the id.DRIVE partnership has officially recruited 25,000 patients across our three studies (surveillance, COVID-19 and RSV vaccine effectiveness) — a remarkable milestone that underscores the strength of our collaboration and the commitment of our partners, study contributors, and participants. Since September 2021, the platform that began with the COVIDRIVE COVID-19 vaccine effectiveness study and continued in 2024 with the three id.DRIVE studies has enrolled 26,536 Severe Acute Respiratory Infection (SARI) patients across seven European countries, involving more than 40 hospitals.
This achievement represents not just a number, but the collective effort of teams across all participating sites who are working tirelessly to advance infectious diseases and vaccine research and improve patient care. Reaching 25,000 patients is a powerful reminder of what we can accomplish together. As we look ahead, id.DRIVE remains dedicated to expanding its studies, strengthening our partnership, and continuing to deliver meaningful scientific outputs.
We extend our deepest gratitude to all the patients, and research teams who made this milestone possible. Here’s to the next 25,000 – and beyond.